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Abstract
Background: Caspase-1 is present in the cytosol as an inactive zymogen and requires the protein complexes
named “inflammasomes” for proteolytic activation. However, it remains unclear whether the proteolytic activity of
caspase-1 is confined only to the cytosol where inflammasomes are assembled to convert inactive pro-caspase-1 to
active caspase-1.
Methods: We conducted meticulous data analysis methods on proteomic, protein interaction, protein intracellular
localization, and gene expressions of 114 experimentally identified caspase-1 substrates and 38 caspase-1 interaction
proteins in normal physiological conditions and in various pathologies.
Results: We made the following important findings: (1) Caspase-1 substrates and interaction proteins are localized in
various intracellular organelles including nucleus and secreted extracellularly; (2) Caspase-1 may get activated in situ in
the nucleus in response to intra-nuclear danger signals; (3) Caspase-1 cleaves its substrates in exocytotic secretory
pathways including exosomes to propagate inflammation to neighboring and remote cells; (4) Most of caspase-1
substrates are upregulated in coronary artery disease regardless of their subcellular localization but the majority of
metabolic diseases cause no significant expression changes in caspase-1 nuclear substrates; and (5) In coronary artery
disease, majority of upregulated caspase-1 extracellular substrate-related pathways are involved in induction of
inflammation; and in contrast, upregulated caspase-1 nuclear substrate-related pathways are more involved in
regulating cell death and chromatin regulation.
Conclusions: Our identification of novel caspase-1 trafficking sites, nuclear and extracellular inflammasomes, and
extracellular caspase-1-based inflammation propagation model provides a list of targets for the future development of
new therapeutics to treat cardiovascular diseases, inflammatory diseases, and inflammatory cancers.
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Background
As a member of the cysteinyl aspartate-specific protease
caspase family, caspase-1 is present in the cytosol as pro-
caspase-1, an inactive zymogen, and requires the assembly
of cytosolic multi-protein complexes known as “inflam-
masomes” for proteolytic activation [1]. These complexes
are assembled intracellularly in response to damage/
danger signal-associated molecular patterns (DAMPs)
and pathogen-associated molecular patterns (PAMPs),
similar to the role of Toll-like receptors (TLRs) at the cell
surface [2]. Activated caspase-1 is required for cleaving/
processing of pro-interleukin-1β (pro-IL-1β) and pro-IL-18
into mature pro-inflammatory cytokines IL-1β and IL-18
in the cytosol, respectively. Additionally, activated
caspase-1 induces other inflammatory pathways by degrad-
ing anti-inflammatory sirtuin-1 (Sirt-1), a nicotinamide
adenine dinucleotide (NAD)-dependent protein/class III
histone deacetylase [3]. Caspase-1 has been shown to in-
duce cell necrosis, pyroptosis, or pyrop-apoptosis [4] and
play a significant role in various developmental stages [5].
However, most of the biological activities of caspase-1
reported so far take place at the post-translational level
(proteolytic processing). Moreover, it remains unclear
whether all the substrates of caspase-1 are only localized
in the cytosol where inflammasomes are assembled to
convert inactive pro-caspase-1 to active caspase-1.
The regulatory effects of caspase-1 on gene expression
have been reported in the intestine [6], liver [6], and
adipose tissue [7]. In addition, we also have reported
several significant findings on the expression and roles of
caspase-1 in vascular inflammation: (1) Nod (nucleotide-
binding and oligomerization domain)-like receptors,
inflammasome components, and caspases are differentially
expressed in human and mouse tissues [8]; (2) Caspase-1
can recognize extended cleavage sites on its natural
substrates [9]; (3) Early hyperlipidemia promotes endothe-
lial activation/dysfunction [10] via a caspase-1–Sirt-1 path-
way [11]; (4) Inhibition of caspase-1 activation improves
angiogenesis [12]; (5) Caspase-1 weakens the progenitor
cell [13] -mediated vessel repair [14] in hyperlipidemia; (6)
Caspase-1 mediates chronic kidney disease-promoted
neointima hyperplasia of the carotid artery [15], and (7)
Hyper-homocysteinemia, an independent risk factor for
cardiovascular disease, induces caspase-1-mediated pyrop-
apoptosis [4].
Despite all these findings of biological functions of
caspase-1, it is not clear whether the caspase-1 activity is
limited only to the cytosol. Variety of inflammasome
assemblies are mainly recognized to be functional in the
cytosol [16]. In addition to well-characterized caspase-1
substrates interleukin-1β (IL-1β) and IL-18 [17], we and
others previously reported that caspase-1 cleaves Sirt-1,
a histone deacetylase, predominantly found in the nucleus,
which is a clear indication that the function of caspase-1
may extend to other subcellular compartments such as
nucleus [3, 11]. Similarly, as we previously reported,
caspase-1 (enzyme ID: EC 3.4.22.36) cleaves many other
protein substrates including those listed in the Brenda
enzyme database [9, 18], and nuclear transcription factors
such as GATA-Binding Protein 4 (GATA4) [19] and
peroxisome proliferator-activated receptor γ (PPARγ) [20].
This provides further validation that caspase-1 and its
inflammasome components may play a role in intracellu-
lar compartments other than the cytosol.
In supporting our argument, a recent report showed
that a well-established component of inflammasome
complex called NLRP3/NALP3 [NLR (nucleotide-binding
oligomerization domain-like (Nod)-like receptor) family
pyrin domain containing 3] acts as a transcription regula-
tor of type 2 T helper cell (Th2) differentiation [21].
NLRP3 is a well-characterized NLR and contains NACHT
[a domain present in NAIP (neuronal apoptosis inhibitor
protein), C2TA (MHC class 2 transcription activator),
HET-E (incompatibility locus product from Podospora
anserina), and TP-1 (telomerase protein-1)], LRR (leucine-
rich repeat), and PYD (pyrin) domains. Moreover, it was
reported that caspase-1 can be activated in the nucleus
[22, 23], suggesting the possibility of caspase-1 being a
direct regulator of gene expression. In addition to regu-
lating non-classic secretory pathway [24], caspase-1 is
also found in extracellular secretory exosomes, which
further prove that caspase-1 is functional outside the
cytosol. Together with our findings and others’, we
hypothesized that caspase-1 play a dynamic role by traf-
ficking to various subcellular organelles and regulate
variety of biological functions by interacting and
cleaving its protein substrates (Fig. 1a).
Since previous reports showed that enzymatic activities
reflect the subcellular localization of enzyme [25] and that
protein localization features can also predict protein func-
tions [26], we conducted an extensive analysis on reported
data to test our hypothesis. We have included our data
mining strategy which we have utilized in our previous
publications in the “Methods” section. Our comprehensive
analysis yielded the following significant and novel findings
of caspase-1: (1) intracellular localization of its substrates
and interaction proteins indicate that caspase-1 traffics
extensively to various intracellular organelles including
mitochondria, nucleus, and extracellular space; (2) 7 out
of 27 caspase-1 nuclear substrates and 3 of 7 nuclear
interaction proteins have transcription regulatory func-
tions, suggesting that caspase-1 regulates gene transcrip-
tion; and (3) caspase-1, 23 caspase-1 substrates, and 2
caspase-1 interaction proteins are secreted extracellularly,
suggesting the possibility of caspase-1-mediated propaga-
tion of inflammation from cell to cell or to remote cells
via circulation. Our findings may eventually lead to future
development of novel therapeutics for the treatment of
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Fig. 1 (See legend on next page.)
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chronic sterile inflammations such as cancers and cardio-
vascular diseases.
Methods
Search for the intracellular localization of caspase-1
substrates and caspase-1 interaction proteins
We have utilized a novel approach which is illustrated in
Fig. 1b. We analyzed 114 experimentally verified caspase-1
substrates that were updated in recently published reports
and review [9, 27, 28]. These substrates were identified
by utilizing proteomic approaches. In addition, we ex-
amined 38 experimentally identified human caspase-1
interaction proteins reported in the NIH-NCBI-Gene
database [29]. All of the caspase-1 interaction proteins
were experimentally verified in previous publications
listed in PubMed (all the references are included in
Additional file 1: Table S3). The identification methods
that were used in these publications included biochem-
ical activity, affinity capture-mass spectrometry, affinity
Capture-Western blot, two hybrid systems, and recon-
stituted complex.
Then we analyzed the subcellular localization of these
experimentally verified caspase-1 substrates and inter-
action proteins in two widely used protein intracellular
localization databases named as Compartments subcel-
lular location database [30] and UniProtKB/Swiss-Prot
location database (European Bioinformatics Institute) [31].
To demonstrate the reliability of these databases, sub-
cellular localization of 21 generally accepted intracellular
organelle markers were analyzed and presented
(See figure on previous page.)
Fig. 1 The key knowledge gaps of the current caspase-1 model and the flow chart of our database mining strategy. a The key knowledge gaps
between the current model and the newly proposed caspase-1 trafficking model. The new model suggests that caspase-1 may traffic to various
subcellular organelles to interact and cleave its substrates and regulate variety of biological functions. b Flow chart of database mining strategy
and three parts of data organization. We propose caspase-1 has two new working models: (1) caspase-1 gets activated in situ in the nucleus as novel
nuclear inflammasome in response to intra-nuclear danger signals; (2) caspase-1 cleaves its substrates in exocytotic secretory pathways including exo-
somes to propagate inflammation to neighboring and remote cells
Table 1 6/20 NLRs are localized in nucleus, suggesting assembly of a variety of nuclear inflammasomes. Several NLR proteins have
potential to form nuclear inflammasome with caspase-1
Symbol Source Subcellular localizations (probabilities)
Database 1a Database 2b Summary
High Middle Low
NOD1 1 PM Cytosol Nucleus Cytoplasm Cytoplasm
NOD2 1 Cytoskeleton PM Cytosol Cytoplasm Cytoplasm
NOD3 1 Cytoplasm Cytoplasm Cytoplasm
NOD4 1 Cytosol Nucleus Cytoskeleton Cytoplasm Cytoplasm
NALP1 1 Cytosol Nucleus Nucleus Nucleus
NALP2 1 Cytosol Nucleus Cytoplasm
NALP3 1 Cytosol Extracellular Nucleus Nucleus Nucleus
NALP4 1 Extracellular Cytosol Extracellular
NALP5 1 Nucleus Mito Cytosol Nucleus Nucleus
NALP6 1 Nucleus PM Cytosol Nucleus Nucleus
NALP7 1 Cytosol Cytosol
NALP9 1 Cytoplasm Cytoplasm Cytoplasm
NALP10 1 PM Nucleus Cytosol Cytoplasm PM
NALP12 1 Cytosol Cytoplasm Cytosol
NALP14 1 Cytosol Cytosol
NAIP 1 Extracellular PM Nucleus Extracellular
IPAF 1 Cytosol Nucleus Cytoskeleton Cytosol Cytosol
IFI16 2 Nucleus Cytosol Nucleus Nucleus
Abbreviation: 1 from published paper (PMID:19505385), 2 from published paper (PMID:25466628), PM plasma membrane, ER endoplasmic reticulum, Mito mitochondrion
aCompartments subcellular location database
bUniProtKB/Swiss-Prot location database
*Candidate nuclear inflammasome molecules
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in Additional file 1: Table S1. This table includes the
PubMed IDs of publications where these organelle markers
were experimentally utilized, which implicates that the two
database sources that we used are extremely reliable to pre-
dict the subcellular localizations of proteins of interest.
Expression profile of caspase-1 substrates and interaction
proteins in human disease, and mouse disease models
Gene expression profile of identified caspase-1 substrates
and its interaction proteins were analyzed in 13 micro-
array datasets extracted from NIH-GEO database (Fig. 1b).
Specific samples were chosen as disease or treatment
groups and parallel controls. The number of samples
was always greater than three except for the pooled
samples. First, we selected the genes with significant
expression changes (p < 0.05) in the microarray data set
and examined the fold change of the genes of our interest.
The genes with more than onefold expression change were
defined as the upregulated genes while genes with their
expression changes less than onefold were defined as
downregulated genes.
Ingenuity Pathway Analysis
We utilized Ingenuity Pathway Analysis (IPA, Ingenuity
Systems, www.ingenuity.com) to characterize clinical rele-
vance and molecular and cellular functions related to the
identified genes in our microarray analysis. The differen-
tially expressed genes were identified and uploaded into
IPA for analysis. The core and pathways analysis was used
to identify molecular and cellular pathways.
Results
Caspase-1 substrates are localized in various intracellular
organelles including nucleus and also secreted
extracellularly
The well-accepted working model of caspase-1 is that the
dormant pro-caspase-1 undergoes self-cleavage and be-
comes activated in the cytosolic protein complex termed
inflammasome, which is assembled in response to external
and internal danger signals. Once being activated,
caspase-1 gains its ability to cleave its substrates; there-
fore, it cleaves cytosolic pro-IL-1β and pro-IL-18 into ma-
ture IL-1β and IL-18 respectively. Then these cytokines
get secreted extracellularly to propagate inflammation.
Therefore, we reasoned that if the current model is valid,
all the caspase-1 substrates should be localized in the
cytosol in order to get access to caspase-1-mediated cleav-
age. However, recent reports from our lab and others’
challenged this working model. We and others demon-
strated that caspase-1 cleaves Sirt-1 [3, 10], which is a nu-
clear localized histone deacetylase. Moreover, caspase-1-
mediated cleavage of nuclear transcription factors such as
GATA-Binding Protein 4 (GATA4) [19] and peroxisome
proliferator-activated receptor γ (PPARγ) [20] was also
reported. Thus, we hypothesized that caspase-1 can traffic
to subcellular locations outside the cytosol to fulfill its
catalytic functions.
To examine this hypothesis, we analyzed the subcellu-
lar localization of caspase-1 substrates and its interaction
proteins in widely used databases named Compartments
subcellular location database and UniProtKB/Swiss-Prot
location database. We tested the reliability of these
databases by identifying the intracellular localization of
experimentally verified 21 well-known organelle marker
proteins. In our test, we included two plasma membrane
proteins, two cytosolic proteins, two endosome proteins,
three endoplasmic reticulum (ER) proteins, three Golgi
proteins, three mitochondrial proteins, three cytoskeletal
proteins and three nuclear proteins (Additional file 1:
Table S1). We found that all of the intracellular organ-
elle marker proteins are identified in these two databases
to be localized in their intrinsic organelles as reported
(see the PubMed IDs of the related papers), suggesting
that these two protein intracellular localization databases
are highly reliable.
Then, we analyzed the intracellular localization of
114 newly experimentally verified caspase-1 substrates
(Additional file 1: Table S2) and found that 22 of these
caspase-1 substrates are secretory proteins, 5 are plasma
membrane proteins, 3 Golgi proteins, 7 ER proteins, 1
Table 2 Pro-caspase-1 and inflammasome components traffic into nucleus and form active inflammasomes that activate caspase-1 in situ
Inflammasome components Function Location Translocation PMID
ASC ASC-b Inflammasome adaptor Cytoplasm Nucleus 20482797
ASC-c Inflammasome adaptor Cytoplasm Nucleus
ASC-d Cytosol Nucleus
Pro-caspase-1 Pro-caspase-1 and caspase prodomain promote translocation Cytosol Nucleus 9726961
NLRP3 Nuclear DNA-binding transcription factor Cytosol Nucleus 26098997
NLRA Control transcription, inflammasome formation and transcriptional activity Nucleus 26194278
NLRC5 Control transcription, inflammasome formation and transcriptional activity Nuclear 26194278
Abbreviation: ASC apoptosis-associated speck-like protein containing a carboxy-terminal CARD, NLR nucleotide-binding oligomerization domain-like (Nod)-like
receptor, PMID PubMed identifier
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mitochondrial protein, 14 cytoskeleton proteins, 32
cytosolic proteins, 28 nuclear proteins, and 2 endosomal
proteins. The results suggested that 28% of the identified
caspase-1 substrates are present in the cytosol and comply
well with the current accepted model of caspase-1 while
rest of the 72% of the substrates are generally localized
elsewhere other than in the cytosol. Most surprisingly,
25% caspase-1 substrates are localized in the nucleus
and 19% caspase-1 substrates are secreted extracellu-
larly. This clearly suggested that the current model
cannot be applied to majority of experimentally verified
caspase-1 substrates as there is a 72% probability that
caspase-1 may traffic to other subcellular organelles to
exert its catalytic functions (Fig. 2a).
Caspase-1 interaction proteins are localized in various
intracellular organelles including nucleus and secreted
extracellularly
To consolidate our finding that the majority of caspase-1
substrates are localized in subcellular compartments
other than the cytosol, we analyzed whether the caspase-1-
interacting proteins that are required for caspase-1
function are also found in these subcellular domains.
We reasoned that if the current model is valid, all the
experimentally validated caspase-1 interaction proteins
should be localized in the cytosol in order to get access
to caspase-1 for interaction. Although various types of
protein interactions share the same sets of interacting
bonds, enzyme-substrate interaction may additionally
require accurate binding orientation to enzyme active
site for catalytic activities [32].
As elaborated in the “Methods” section, we identified
38 experimentally verified caspase-1 interaction proteins
and analyzed their intracellular localization (Additional
file 1: Table S3). Our results indicated that 2 caspase-1
interaction proteins are secretory proteins, 6 are plasma
membrane proteins, 1 Golgi protein, 3 ER proteins, 2 mito-
chondrial proteins, 2 cytoskeleton proteins, 14 cytosolic
proteins, 7 nuclear proteins, and 1 endosomal protein.
Once again, the results derived from the analysis of the
intracellular localization of caspase-1 interaction proteins
suggest that, in addition to 37% cytosolic interaction
proteins that correlated well with the current model,
caspase-1 has as high as 63% probability to traffic to
other subcellular organelles to exert its functions by
protein interactions (Fig. 2b). Interestingly, an 18% of
caspase-1 interaction proteins are localized in the nucleus
while 5% of caspase-1 interaction proteins are secreted
extracellularly.
Caspase-1 gets activated in situ in the nucleus in response
to intra-nuclear danger signals
Recently, we and others found that a histone deacetylase
Sirt-1, a protein predominantly localized in the nucleus
Fig. 2 Caspase-1 substrates and interaction proteins are present in cellular compartments other than the cytosol. a There are 114 newly
experimentally verified caspase-1 substrates: 22 of these caspase-1 substrates are secretory proteins, 5 are plasma membrane proteins, 3 Golgi
proteins, 7 ER proteins, 1 mitochondrial protein, 14 cytoskeleton proteins, 33 cytosolic proteins, 28 nuclear proteins, and 2 endosomal proteins.
28% of the identified caspase-1 substrates are present in the cytosol while the rest of the 72% of the substrates are generally localized elsewhere
other than in the cytosol. 25% caspase-1 substrates are localized in the nucleus and 19% caspase-1 substrates are secreted extracellularly. b Out of 38
experimentally verified caspase-1 interaction proteins, 6 caspase-1 interaction proteins are secretory proteins, 7 are plasma membrane proteins, 1 Golgi
protein, 3 ER proteins, 2 mitochondrial proteins, 2 cytoskeleton proteins, 18 cytosolic proteins, 11 nuclear proteins, and 1 endosomal protein. In
addition to 35% cytosolic interaction proteins, caspase-1 has as high as 63% probabilities to traffic to other subcellular organelles to form
protein interactions. 21% of caspase-1 interaction proteins are localized in the nucleus and 11% of caspase-1 interaction proteins are
secreted extracellularly
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as suggested by the GeneCards database [33], is specif-
ically cleaved by caspase-1 in human aortic endothelial
cells in response to pro-atherogenic stimuli such as
oxidized low density lipoprotein (oxLDL) [11]. Further,
caspase-1 cleaves Sirt-1 in apolipoprotein E-deficient
(ApoE−/−) mouse aorta in response to high-fat diet feeding
[11], and in adipose tissue in response to high-fat diet-
induced metabolic dysfunction [3]. In addition, protein
nuclear transcription factors such as GATA-Binding
Protein 4 (GATA4) [19] and peroxisome proliferator-
activated receptor γ (PPARγ) [20] were also found to be
caspase-1 substrates.
These findings raise an important question to be
addressed, that is whether pro-caspase-1 traffics to the
nucleus and get activated in the nucleus or activated
caspase-1 traffics to the nucleus. A previous report by
Mao et al. showed that tumor necrosis factor-α
(TNF-α) induces apoptosis by triggering trafficking of
pro-caspase-1, but not activated caspase-1, into the nu-
cleus and getting caspase-1 activated in situ [22]. Since
pro-caspase-1 requires assembly of inflammasomes that
consists of two other proteins [17] including a nucleotide-
binding oligomerization domain-like (Nod)-like receptor
(NLR) and apoptosis-associated speck-like protein con-
taining a carboxy-terminal CARD (ASC), we hypothesized
that in order to get pro-caspase-1 activated in the nucleus,
these inflammasome components should also be localized
in the nucleus as well. In supporting our argument, a
recent report showed that NLRP3/NALP3, a well-
characterized NLR, is a nuclear transcription regulator
of type 2 T helper cell (Th2) differentiation [21]. More-
over, it was also reported that ASC is predominantly
localized in the nucleus in resting human monocytes/
macrophage and is trafficked to cytosol to form an
active inflammasome in response to pathogen infection
[34]. All these findings suggest the possibility of the
presence of NLRP3 inflammasome in the nucleus.
There are about 20 NLRs expressed in human genome
[8]; therefore, we analyzed the subcellular localization of
all the 20 NLRs. As shown in Tables 1 and 2, six out of
20 NLRs examined including NALP1, NALP3, NALP5,
NALP6 (Table 1), NLRA, and NLRC5 (Table 2) are local-
ized in the nucleus. Since an inflammasome is composed
of one type of NLR, ASC, and pro-caspase-1, our results
suggested that several types of nuclear inflammasomes
can be assembled to get caspase-1 activated in the nucleus
for regulating inflammation. Our argument is supported
by a recent report by Kerur et al., who demonstrated
that during Kaposi sarcoma-associated herpes virus in-
fection in endothelial cells, interferon gamma-inducible
protein 16 (IFI16) interacts with the adaptor molecule
ASC and pro-caspase-1 to form a functional nuclear
inflammasome [35]. IFI16 (NCBI Protein database ID:
NP_001193496) has 729 amino acids and is a member
of the HIN-200 (hematopoietic interferon-inducible nu-
clear antigens with 200 amino acid repeats) family of
cytokines. IFI16 has also caspase activation and recruit-
ment domain CARD and pyrin domain [36], which is
functionally similar to other NLRs. The nuclear inflamma-
somes may be functional for sensing nuclear danger sig-
nals including DNA virus infections [35], TNF-α
induced apoptosis [22] (DNA fragmentation), GATA4
[19] -mediated cardiac development, and PPARγ [20]
-mediated adipocyte differentiation, and enhancing insulin
resistance [37], Sirt-1 degradation-triggered pro-
inflammatory process [11], and other genome regulation
dysfunctions [38]. We have summarized the nuclear
danger signals reported so far in Additional file 1: Table
S4. In addition, our results also showed that 6 out of
27 caspase-1 nuclear substrates (Table 3) and 3 of 7
interaction proteins (Table 4) have transcription
regulatory functions, suggesting that caspase-1 is a
potential gene regulator.
Caspase-1 cleaves substrates on exocytotic secretory
pathways to propagate inflammation to neighboring and
remote cells
Current understanding on the cytosolic roles of caspase-
1 in promoting inflammation is based on the following
findings: (1) processing pro-IL-1β and pro-IL-18 into
mature IL-1β and IL-18 [11, 17]; (2) facilitating non-
classical secretory pathway [24]; and (3) causing inflam-
matory cell death (pyroptosis) or pyrop-apoptosis with
plasma membrane rupture, which is in striking contrast
to the apoptosis with the features of membrane blebbing
and no inflammation [17]. If this was the case, then all
the caspase-1 substrates, caspase-1 itself, and inflamma-
some components should not be localized extracellu-
larly. However, several recent reports challenged this
working model [39, 40].
To re-visit this issue, we examined whether caspase-1
substrates, caspase-1, and inflammasome components
are localized extracellularly and whether extracellular
substrates of caspase-1 can be found in exosomes by
searching the UniProKB database. As shown in Table 5,
19 out of 23 caspase-1 substrates localized extracellularly
are found in the exosomes, where 8 of these substrates
were experimentally verified.
Therefore, this raises the question whether pro-caspase-
1 gets activated extracellularly in inflammasomes localized
in extracellular vesicles. To explore this possibility, a re-
cent report found that microbes or danger signals trigger
inflammasome sensors, which induce polymerization of
the adapter ASC leading to assembly of an ASC speck.
The ASC specks can recruit and activate caspase-1 and in-
duce IL-1β and IL-18 cytokine maturations that result in
pyroptotic cell death [39]. After pyroptosis, ASC specks
are accumulated in the extracellular space, which further
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promotes IL-1β cytokine maturation [39], although the
finding was disputed by others that ASC complex without
NLRP3 is unable to get caspase-1 activated [41]. Along
the same line, another report showed that upon activation
of caspase-1, oligomeric NLRP3 inflammasome particles
were released from macrophages. Recombinant oligo-
meric protein particles composed of the adaptor ASC
or the p.D303N mutant form of NLRP3 associated with
cryopyrin-associated periodic syndromes (CAPS) stimu-
late further activation of caspase-1 extracellularly, as well
as intracellularly after phagocytosis by surrounding
macrophages [40]. Moreover, caspase-1 is found to be
activated in exosomes [42], which can carry caspase-1,
cross the injured blood-spinal cord barrier, and deliver the
cargo in vivo. Taken together, these analyses suggest that
pro-caspase-1 can get activated in extracellular space and
Table 3 6/27 caspase-1 nuclear substrates have transcription regulatory functions
Substrate Location summary Transcription factor Inflammation
PAZAR TF (ID) NCBI Inflammatory function PMID
HSPB3 Nucleus
HNRNPA2B1 Nucleus Pro-inflammation 26030368
SMG7 Nucleus Pro-inflammation 21467779
TFAP2A Nucleus TF0000385 a Pro-inflammation 10504447
PTPN18 Nucleus
MCM3 Nucleus Pro-inflammation 12421976
VPS72 Nucleus
EEF1A1 Nucleus TF0000325 Pro-inflammation 22829547
LMNA Nucleus Pro-inflammation 18551513
GIT2 Nucleus Pro-inflammation 16715100
PCBP2 Nucleus Pro-inflammation 19740317
PARP1 Nucleus Pro-inflammation 17430886
ATXN3 Nucleus Pro-inflammation 11466410
U2AF2 Nucleus









PPARG Nucleus TF0000041 a Pro-inflammation 11089900
NONO Nucleus
MCM5 Nucleus Anti-inflammation 10551502
TRIM28 Nucleus TF0000281 a Anti-inflammation 22995936
Abbreviation: PAZAR TF Transcription factor database (http://www.pazar.info/cgi-bin/tf_search.cgi), NCBI National Center of Biotechnology Information,
PMID PubMed identifier
aGenes are confirmed in NCBI
Table 4 3/7 caspase-1 interaction proteins have transcription
regulatory functions









Abbreviation: CASP1 caspase-1, NCBI National Center of Biotechnology Information
aGenes are confirmed in NCBI
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that caspase-1 cleaves its substrates in exocytotic secretory
pathways including exosomes to propagate inflammation
to neighboring and remote cells.
Most of caspase-1 substrates are upregulated in coronary
artery disease (CAD) regardless of their subcellular
localization, but different metabolic diseases cause no
significant expression changes in caspase-1 nuclear
substrates
We hypothesized that if caspase-1 trafficking plays a role in
metabolic and autoimmune diseases, the expression and
the subcellular localization of caspase-1 substrates may be
altered due to changes in the caspase-1 activity. To test this
hypothesis, we analyzed RNA transcript expression of the
caspase-1 substrates in the microarray datasets deposited in
the NIH-NCBI-GEO Datasets database [43].
We examined the expression of caspase-1 substrates
in eight disease conditions including coronary artery dis-
ease (CAD), metabolic syndrome (MS), type 2 diabetes
(T2D), morbidly obese (MO), rheumatoid arthritis (RA),
and hypertension. GSE9490 microarray was conducted in
vitro on aortic smooth muscle cells in the presence of low
and high homocystein (10 μM homocysteine (Hcy) and
100 μMHcy). As shown in Table 6, we made the following
findings: (1) 65 out of 114 (56.5%) caspase-1 substrates are
upregulated in coronary heart disease regardless of their
subcellular localization, suggesting that caspase-1 and its
substrates play a significant role in the pathogenesis of the
disease; (2) the majority of metabolic diseases including
metabolic syndrome (MS), type 2 diabetes (T2D), mor-
bidly obese (MO), hypertension, and homocystein treat-
ment on aortic smooth muscle cells did not cause
significant caspase-1 substrate expression changes, 6.1%
(MS), 10.4% (T2D), 5.2% (MO), 5.2% (hypertension), and
6.1% (homocystein treatment on aortic smooth muscle
cells); (3) metabolic diseases including metabolic syn-
drome, type 2 diabetes, morbidly obese, hypertension, and
homocysteinemia have no significant expression changes
in caspase-1 nuclear substrates; and (4) the 5 caspase-1
substrate that are upregulated in rheumatoid arthritis may
play a significant role in the pathogenesis of rheumatoid
arthritis.
Table 5 19/23 caspase-1 substrates are secreted in exosomes, where 8 of them were experimentally verified
Substrate Location summary Extracellular exosome Inflammation
Sourcea PMID Inflammatory function PMID
CA2 Secreted UniProtKB Pro-inflammation 7722336
RNH1 Secreted UniProtKB 19056867
IL18 Secreted UniProtKB 23376485 Pro-inflammation 11203186
LDHB Secreted UniProtKB
TBC1D15 Secreted UniProtKB 23376485
IL1B Secreted UniProtKB Pro-inflammation 10380697
FAA4 Secreted UniProtKB
NUCB2 Secreted UniProtKB Pro-inflammation 16407280
SYAP1 Secreted UniProtKB 18570454
BID Secreted UniProtKB Pro-inflammation 17209037
AK2 Secreted UniProtKB 20458337
TPI1 Secreted UniProtKB 19056867
PPP1CA Secreted
ENO1 Secreted UniProtKB Pro-inflammation 19898480
PSMA7 Secreted UniProtKB
HUWE1 Secreted UniProtKB 19056867
IL33 Secreted UniProtKB Pro-inflammation 18802081
CAT Secreted UniProtKB
CAP1 Secreted UniProtKB 19056867 Pro-inflammation 24606903
ST14 Secreted UniProtKB
IL37 Secreted Pro-inflammation 22047735
ST14 Secreted
NEDD4 Secreted
Abbreviation: PMID PubMed identifier
aUniProtKB/Swiss-Prot location database
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Table 6 Unlike in metabolic diseases, caspase-1 substrates are upregulated in CAD regardless of their subcellular localization
The numbers in the cells represent the fold change with significance. The colors show the regulatory level (red means upregulation and blue means downregulation)
Abbreviation: CAD, coronary artery disease, MS metabolic syndrome, T2D type 2 diabetes, MO morbidly obese, RA rheumatoid arthritis, GEO Gene Expression
Omnibus database, PMID PubMed identifier
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In addition, we examined whether the expression of
38 caspase-1 interaction proteins was changed in these
pathological conditions. As shown in Table 7, the ex-
pression of 6 out of 38 caspase-1 interaction proteins
were changed in metabolic diseases; and 3 and 4
interaction proteins were upregulated in coronary heart
disease and hypertension, respectively. These findings
suggest that the expression changes of caspase-1 inter-
action proteins are not a major regulatory mechanism
for the pathogenesis of the aforementioned diseases.
Furthermore, to strengthen our argument that most of
caspase-1 substrates that are upregulated in coronary heart
disease may have pro-inflammatory functions, we examined
the expression changes of those caspase-1 substrates in
regulatory T cells (Tregs) in comparison to those in T ef-
fector cells in five microarray datasets. As shown in Table 8,
analyzing of four microarray datasets revealed [44] that the
ratios of downregulated caspase-1 substrates versus upregu-
lated substrates were 5/2, 3/3, and 8/4, suggesting that the
caspase-1 substrates downregulated in anti-inflammatory/
immune suppressive Tregs [45] may be pro-inflammatory
in the pathogenesis of coronary heart disease.
In coronary heart disease, upregulated caspase-1 extracellular
substrates are related to inflammatory pathways while
caspase-1 nuclear substrates are more related to pathways
involved in cell death and chromatin regulation
In order to determine the changes of caspase-1 activities
in response to the pathogenesis of coronary artery disease,
we used the Ingenuity Pathway Analysis (IPA) database as
we reported previously [14]. The IPA database is one of
the most comprehensive omics data analyzing databases
[46] available today; we examined the signaling pathways
related to extracellular, cytosolic, and nuclear caspase-1
substrates that were upregulated in coronary artery dis-
ease. As shown in Fig. 3, the top ten pathways identi-
fied from our Ingenuity Pathway Analysis for upregulated
caspase-1 nuclear substrates in coronary artery disease
were death receptor signaling, apoptosis signaling, cell
cycle control of chromosomal replication, splicesomal
cycle, retinoic acid apoptosis signaling, ultraviolet radi-
ation (UVA)-induced mitogen-activated protein kinase
(MAPK) signaling, MAPK-extracellular signal-regulated
kinase (ERK) pathway, double-strand DNA break repair,
telomere extension, and granzyme B signaling. More-
over, as shown in Table 4, three out of seven caspase-1
interaction proteins including androgen receptor (AR),
atrophin-1 (ATN1), and CCAAT/enhancer-binding pro-
tein beta (CEBPB) have transcription regulatory functions.
It is unknown whether caspase-1 interacts with these
proteins and fulfills non-catalytic functions in regulating
gene transcription in the nucleus.
Furthermore, as shown in Fig. 4, we found that the top
ten pathways that are related to upregulated caspase-1
extracellular substrates in coronary artery disease are in-
volved in inflammatory signaling including cytokine che-
mokine secretions, immune responses (graft-versus-host
disease), cytokine signaling, and Toll-like receptor signal-
ing. Taken together, these analyses suggest that in coronary
artery disease, upregulated caspase-1 extracellular sub-
strates are related to inflammatory pathways while up-
regulated caspase-1 nuclear substrates are more related
to pathways that regulate cell death and chromatin
regulation. Surprisingly, most of the cytosolic substrates
upregulated during coronary artery disease are significantly
involved in ER (endoplasmic reticulum) stress signaling
pathway (Additional file 1: Figure S1). Also, our IPA impli-
cated that these upregulated cytosolic substrates may
significantly regulate apoptosis, TNF receptor 1 signaling,
unfolded protein response, and also ubiquitination.
Discussion
Recent progress has clearly demonstrated that caspase-1/
inflammasome pathway plays a critical role in regulating
innate immune system by sensing PAMPs and DAMPs, in-
ducing pro-inflammatory cytokine maturation, promoting
multi-format cell death including inflammatory cell
death (pyroptosis), pyronecrosis [47], and pyrop-apoptosis,
Table 7 Changes in caspase-1 interaction proteins are insignificant in metabolic and inflammatory diseases
The numbers in the cells represent the fold change with significance. The colors show the regulatory level (red means upregulation and blue means downregulation)
Abbreviation: CASP1 caspase-1, ID identification, CAD coronary artery disease, MS metabolic syndrome, T2D type 2 diabetes, MO morbidly obese, RA rheumatoid
arthritis, GEO Gene Expression Omnibus database, PMID PubMed identifier
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inducing histone modification and unconventional
secretion, inhibiting glycolysis, and regulating cell survival
[17, 48], eicosanoid storm, autophagy, and metabolism
[49]. In addition, myocardial-specific overexpression of
caspase-1 induces a significant increase in cardiomyocyte
death in young mice without any increase in tissue or
plasma levels of IL-1β or other inflammatory mediators
[50]. How caspase-1 regulates such broad biological
functions is yet unknown. The current working model
indicates that pro-caspase-1 gets activated in a protein
complex termed inflammasome in the cytosol. How-
ever, if the current model is valid, all the caspase-1
substrates should be all localized in the cytosol, which
has never been comprehensively examined and verified.
In this study, we examined an important issue whether
caspase-1 traffics between intracellular organelles for
cleaving its substrates. To investigate this hypothesis, we
took novel proteomic data analysis, protein interaction
data, and protein intracellular localization database
approaches, and analyzed intracellular localization of
114 experimentally identified caspase-1 substrates and
38 caspase-1 interaction proteins. Our analysis revealed
the following important findings:
1) Caspase-1 substrates and interaction proteins are
localized in various intracellular organelles. Our data
reveals the presence of caspase-1 substrates and
interaction proteins in variety of subcellular
Table 8 Upregulated caspase-1 extracellular and nuclear substrates in CAD are downregulated in anti-inflammatory T cells
The numbers in the cells represent the fold change with significance. The colors show the regulatory level (red means upregulation and blue means downregulation)
Abbreviation: ID identification, KO knock out, Treg regulation T cell, T conventional T cell, GEO Gene Expression Omnibus database, PMID PubMed identifier
Fig. 3 Upregulated caspase-1 nuclear substrates in coronary heart disease induce cell death, chromatin replication, and inflammation
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compartments, indicating the activity of caspase-1
may extend beyond the cytosol. There are experimental
evidence confirming the formation of active
inflammasomes in the nucleus and in extracellular
vesicles, which we have elaborated below. We also
found the presence of caspase-1 substrates and
interaction proteins in Golgi bodies, ER, and
mitochondria. So far, formation of active inflammasomes
and active caspase-1 in these three compartments are
not experimentally verified. Our data suggests that
caspase-1 may play an active role in these organelles that
may contribute to inflammatory disease progression,
therefore emphasizing the need for experimental
verification of its role extensively in subcellular com-
partment other than the cytosol.
2) Caspase-1 gets activated in situ in the nucleus in
response to intra-nuclear danger signals. Previously,
pro-caspase-1 [22] and inflammatory components
such as NLRP3 [51] and ASC (apoptosis-associated
speck-like protein containing a carboxy-terminal
CARD) [34] were found to shuttle between nucleus
and cytoplasm in response to various inflammatory
responses. Interestingly, formation of an active
inflammasome in the nucleus was reported during
viral infections. For an example, Kerur et al. clearly
demonstrated that pro-caspase-1, ASC, and IFI16
make active nuclear inflammasomes that lead to
production of activated caspase-1 in the nucleus in
the presence of Kaposi sarcoma virus (KSHV)
infection in dermal endothelial cells [35]. Also, the
same group had shown that inflammasomes comprised
of IFI16, ASC, and pro-caspase-1 are formed in the
nucleus in response to Epstein-Barr virus (EBV)
infections as well [52]. However, unlike the
inflammasomes that were formed due to KSHV
infection, inflammasomes that are made in response
to EBV infection seem to produce active caspase-1
only in the cytoplasm. Nevertheless, based on our
findings, there is a possibility that these inflammasomes
constructed due to viral infections may trigger cellular
signaling pathways in the nucleus that are yet to be
explored. Even though formation of an active nuclear
inflammasome is not demonstrated, Aries et al.
implicated the presence of active caspase-1 in the
nucleus that cleaves the transcription factor GATA4,
which negatively impacts the cell survival of
cardiomyocytes treated with doxorubicin [19].
Furthermore, we also have demonstrated that
pro-atherogenic stimuli-mediated induction of
active caspase-1 cleaves Sirt-1, a histone deacetylase
predominantly found in the nucleus [11]. How the
active caspase-1 and inflammasome components
shuttle in and out of the nucleus is not clearly
understood. However, presence of nuclear
localization signal (NLS) in the N-terminal of
pro-caspase-1 was previously reported [22]. Nonetheless,
whether caspase-1 and other inflammatory components
in the nucleus play a significant role during the
progression of inflammatory disorders other than
during the viral infections and pharmacological
interventions such as doxorubicin have not been
studied. The nuclear danger signals that are documented
to prompt in situ activation of caspase-1 or
inflammasome formation are summarized in
Additional file 1: Table S4. The data provided in
the current manuscript suggest the possibility of
formation of a variety of active inflammasome
complexes in the nucleus in response to various
stimuli. Also it provides potential nuclear caspase-1
substrates that need experimental validation in the
future.
3) Caspase-1 cleaves its substrates on exocytotic
secretory pathways including exosomes to propagate
inflammation to neighboring and remote cells.
Fig. 4 In coronary heart disease, upregulated caspase-1 extracellular substrate-related pathways mediate inflammation
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Previous reports have provided evidence that
activated caspase-1 is localized in microvesicles shed
by monocytes in response to inflammation [53] and
also that caspase-1 is secreted extracellularly by
Golgi/ER-independent manner [24]. Moreover, it
was also shown that pro-caspase-1 gets activated
extracellularly and processes and induces the secretion
of mature IL-1β from platelet microparticles [54],
which propagates inflammation in a paracrine manner
[40]. Nevertheless, whether or not pro-caspase-1 and
other proteins that form the inflammasomes are
involved in production of active caspase-1 in
membrane vesicles shed by cells is not fully understood.
Our analysis revealed the possibility of formation of
active inflammasome complexes in these vesicles,
which may eventually propagate inflammation via
active caspase-1 under inflammatory stimuli and
pathological conditions.
4) Caspase-1 substrates are upregulated in coronary
artery disease. Previously, we demonstrated that
pro-caspase-1 and its active p20 subunit expression
was significantly upregulated in aortas of ApoE-
deficient mice during early hyperlipidemia (high-fat
diet feeding for 3 weeks) [11]. Moreover, we
demonstrated that caspase-1 deficiency in ApoE−/−
background significantly attenuated the atherosclerotic
lesion formation in aortic sinus of the mice fed with
high-fat diet for 3 weeks [11]. Interestingly, in the
current study, we found that most of caspase-1
substrates are upregulated in coronary artery
disease regardless of their subcellular localization.
Therefore, our findings suggest that caspase-1 and
its substrates may play a crucial role during the
disease progression of coronary artery disease. Also,
a previous publication had demonstrated increased
expression of caspase-1 and NLRP3 inflammasome
in the adipose tissue and liver of obese mice and
humans [55]. Furthermore, the same study implicated
that the level of caspase-1 expression was positively
correlated with the severity of type 2 diabetes in
individuals. However, in the current study, we
could not observe any significant changes in the
expression of caspase-1 substrates in different cellular
compartments in metabolic diseases.
5) Upregulated caspase-1 substrates in different
compartments trigger differential signaling pathways.
In coronary artery disease, majority of upregulated
caspase-1 extracellular substrates are components
of inflammatory signaling pathways; and in contrast,
most of the upregulated caspase-1 nuclear substrates
are involved in cell death and chromatin regulation.
Also, our analysis revealed that the upregulated
cytosolic caspase-1 substrates in coronary artery
disease regulate ER stress (Additional file 1: Figure S1).
Previous publications have confirmed that ER stress
can be a potential intracellular danger signal for
caspase-1 activation (Additional file 1: Table S4).
Thus, our data suggests potential downstream targets
of caspase-1 that may play a significant role in
inflammatory disorders such as coronary artery
disease. Further studying of these substrates and
interaction proteins may reveal probable targets
that can be therapeutically intervened for treatment
of chronic inflammatory disorders in the future.
Our analysis revealed potential novel substrates and
interaction proteins of caspase-1 that may exert biological
effects in various cellular compartments and induce
diverse reactions. However, recent work also provides the
evidence that the biological effects exerted by caspase-1
do not solely depend on its protease activity. In contrast
to its usual inhibitory effects on proteins by proteolytic
cleavage, caspase-1 was found to activate caspase-7 [56]
and also increase the activity of NF-kB independent of its
enzymatic activity [57]. Furthermore, caspase-1 activity
can be regulated by post-translational modifications such
as deubiquitination and glutathionylation [58, 59]. There-
fore, this suggest that the function of caspase-1 is far more
intricate and it may interact with some of its substrates
and interactions proteins via non-canonical pathways,
which are yet to be elucidated.
We conducted a comprehensive analysis on raw
data available in databases that contained information
that were already experimentally validated, and hence,
our work deviates from a traditional literature review where
a summary is presented on the already existing literature.
All the publications that we have cited in this article is to
further strengthen and validate the novel working model of
caspase-1 we proposed. Furthermore, the models we sug-
gest here were based on experimentally generated data but
not on bioinformatics predictions although bioinformatics
approaches have significantly improved our understanding
on many complex biological issues [60]. All the caspase-1
substrates analyzed in this study were reported previously
[27, 28] and were identified using mass-spectrometry-based
proteomic approaches. To enhance the strengths of the
data, we verified the reliability of two different subcellular
localization databases [31] of proteins [30] by analyzing 21
well-characterized subcellular organelle protein markers. In
analyzing the caspase-1 substrate expression changes, we
analyzed the microarray experimental data sets deposited
in the NIH-GEO Datasets database.
One of the limitations in this manuscript is that the
data presented relies mainly on microarray data, which
depicts gene expression changes but may not necessarily
reflect the protein expression. Furthermore, we acknow-
ledge that the list of caspase-1 substrates and interact
proteins were obtained only from in vitro experiments
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Fig. 5 (See legend on next page.)
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that intracellular compartmental structures are not well
maintained. However, most of the caspase-1 substrates
and the interaction proteins identified in this study seem
to exist in cellular compartments other than the cytosol.
Therefore, further studies should be conducted to de-
termine the pathophysiological relevance of caspase-1
cleavage of the identified substrates and caspase-1
binding to no-substrate interaction proteins in vivo and
also in clinical settings.
Conclusions
Our new results and others’ recent papers allow us to
propose a new working model illustrated in Fig. 5a: first,
in response to the stimulation of conditional and classical
DAMPs [61] and PAMPs, caspase-1 can be activated in
inflammasome complexes in cytosol, nucleus and extra-
cellularly; second, several types of novel nuclear inflam-
masomes can be assembled and get pro-caspase-1
activated in situ in the nucleus in response to intra-
nuclear danger signals related to cell death and chro-
matin regulation; third, cytosolic inflammasomes and
novel extracellular inflammasomes are more func-
tional in promoting inflammation in response to
extracellular and cytosolic danger signals; fourth, due
to various factors listed in Fig. 5b, cells are heteroge-
neous in the speed in activating caspase-1 and initiat-
ing inflammation in responding to extracellular and
cytosolic danger signals, which we coined the term as
inflammation privilege in 2009 [8]. The cells respond
to danger signals first will propagate the inflammation
via sending out activated caspase-1-based exosomes
and ASC specks, which can be uptake by neighboring
and remote cells that are relatively slower in sensing dan-
ger signals and make those cells inflamed. Our identifica-
tion of novel caspase-1 trafficking organelles, nuclear
inflammasomes, extracellular inflammasomes and extra-
cellular caspase-1-based inflammation propagation model
significantly improves our understanding of caspase-1
function and provides a list of targets for the future de-
velopment of new therapeutics to treat cardiovascular
diseases, inflammatory diseases, and inflammatory
cancers.
Additional file
Additional file 1: Table S1. Analysis of 21 experimentally verified
subcellular markers to confirm the reliability of two different databases.
Table S2. 114 experimentally identified caspase-1 substrates are localized
in various organelles including nucleus and secreted extracellularly. Table S3.
38 experimentally verified caspase-1 interaction proteins are localized in
various intracellular organelles. Table S4. Danger signals involved in
inflammasome activation. Figure S1. In coronary artery disease, the
signal pathway of caspase-1 upregulated cytosolic, nuclear and extracellular
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